Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L611463-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $300.90 | |
L611463-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $941.90 |
Synonyms | LB 42908 |
---|---|
Specifications & Purity | Moligand™ |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of farnesyltransferase; CAAX box; beta |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 1-(1-{[1-(3a,7a-dihydro-2H-1,3-benzodioxol-5-ylmethyl)-1H-imidazol-5-yl]methyl}-4-(naphthalen-1-yl)-1H-pyrrole-3-carbonyl)-4-methylpiperazine |
---|---|
INCHI | InChI=1S/C32H33N5O3/c1-34-11-13-36(14-12-34)32(38)29-20-35(19-28(29)27-8-4-6-24-5-2-3-7-26(24)27)18-25-16-33-21-37(25)17-23-9-10-30-31(15-23)40-22-39-30/h2-10,15-16,19-21,30-31H,11-14,17-18,22H2,1H3 |
InChi Key | VZWZHIJGBPHRDI-UHFFFAOYSA-N |
Canonical SMILES | CN1CCN(CC1)C(=O)c1cn(cc1c1cccc2c1cccc2)Cc1cncn1CC1=CC2C(C=C1)OCO2 |
Isomeric SMILES | CN1CCN(CC1)C(=O)C2=CN(C=C2C3=CC=CC4=CC=CC=C43)CC5=CN=CN5CC6=CC7C(C=C6)OCO7 |
PubChem CID | 91623355 |
CAS Registry No. | 226927-89-5 |
---|---|
PubChem CID | 91623355 |
Reactome Reaction | R-HSA-9647987 |
Reactome Drug | R-ALL-9656772 |
Enter Lot Number to search for COA:
1. Lee H, Lee J, Lee S, Shin Y, Jung W, Kim JH, Park K, Kim K, Cho HS, Ro S et al.. (2001) A novel class of highly potent, selective, and non-peptidic inhibitor of Ras farnesyltransferase (FTase).. Bioorg Med Chem Lett, 11 (23): (3069-72). [PMID:11714612] [10.1021/op500134e] |
2. Downward J. (2003) Targeting RAS signalling pathways in cancer therapy.. Nat Rev Cancer, 3 (1): (11-22). [PMID:12509763] [10.1021/op500134e] |